Rich Segal

Bio:

Rich represents high-growth companies, investment banks and institutional investors in equity and debt offerings, with a focus on the life sciences, technologu and consumer/retail sectors. Rich also counsels public companies on US Securities and Exchange Commission compliance and reporting, and he advises private companies on a broad range of corporate and securities matters.

Since 2019, Rich has completed 140+ securities transactions, including 39 initial public offerings, that raised more than $34 billion for companies such as:

Akero Therapeutics*
Alarm.com
Apellis Pharmaceuticals*
Argenx*
Avidity Biosciences*
Datadog
DBV Technologies
DigitalOcean
Karuna Therapeutics*
Legend Biotech
Prelude Therapeutics*
Rapport Therapeutics*
Tempus AI
The Clorox Company*
Verve Therapeutics*
Warby Parker*
Zenas BioPharma
* Indicates investment bank representation

Rich also regularly represents investment banks, including BofA Securities, Barclays Capital, BMO Capital Markets, Canaccord Genuity, Cantor Fitzgerald, Citigroup Global Markets, Deutsche Bank Securities, Evercore Group, Goldman Sachs, H.C. Wainwright & Co., Jefferies, JMP Securities, J.P. Morgan Securities, Leerink Partners, Morgan Stanley, Needham & Company, Nomura Securities International, Oppenheimer & Co., Piper Sandler, Raymond James & Associates, RBC Capital Markets, Robert W. Baird & Co., Stifel, TD Securities, UBS Securities, Wedbush Securities, Wells Fargo and William Blair & Company.